Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-26 DOI:10.1080/14796694.2025.2454895

Francesco Passamonti, Siddhi Korgaonkar, Rohan C Parikh, Manoj Chevli, Aylin Yucel, Julien Rombi, Shalon Jones, Dorothy Zissler, Keith L Davis, Samantha Slaff

{"title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.","authors":"Francesco Passamonti, Siddhi Korgaonkar, Rohan C Parikh, Manoj Chevli, Aylin Yucel, Julien Rombi, Shalon Jones, Dorothy Zissler, Keith L Davis, Samantha Slaff","doi":"10.1080/14796694.2025.2454895","DOIUrl":null,"url":null,"abstract":"Aim: Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX).Patients & methods: This study was a retrospective, noninterventional medical record review of patients in Canada, Germany, and the United Kingdom (UK). A total of 70 physicians (primarily hematologist-oncologists [78.6%]) provided data for 196 eligible patients.Results: Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years. Median treatment duration was 11.5 months (median follow-up, 13.8 months), and nearly half (49.5%) of patients initiated FEDR at the label-indicated dose of 400 mg daily. Six months post-initiation, 77.7% and 66.8% of patients experienced symptom and spleen response, respectively. Kaplan-Meier estimates of median progression-free and overall survival from initiation were 23.8 months (95% CI, 21.1-27.6) and 29.8 months (95% CI, 23.9-NE), respectively.Conclusion: These findings demonstrate real-world FEDR effectiveness among patients with myelofibrosis who discontinued RUX.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"579-591"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845104/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2454895","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX).

Patients & methods: This study was a retrospective, noninterventional medical record review of patients in Canada, Germany, and the United Kingdom (UK). A total of 70 physicians (primarily hematologist-oncologists [78.6%]) provided data for 196 eligible patients.

Results: Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years. Median treatment duration was 11.5 months (median follow-up, 13.8 months), and nearly half (49.5%) of patients initiated FEDR at the label-indicated dose of 400 mg daily. Six months post-initiation, 77.7% and 66.8% of patients experienced symptom and spleen response, respectively. Kaplan-Meier estimates of median progression-free and overall survival from initiation were 23.8 months (95% CI, 21.1-27.6) and 29.8 months (95% CI, 23.9-NE), respectively.

Conclusion: These findings demonstrate real-world FEDR effectiveness among patients with myelofibrosis who discontinued RUX.

查看原文本刊更多论文

使用联邦拉替尼治疗骨髓纤维化患者的现实世界治疗模式和健康结果

目的：评估现实世界中，ruxolitinib （RUX）停药后原发性或继发性骨髓纤维化患者的federatinib （FEDR）治疗模式和临床结果。患者和方法：本研究对加拿大、德国和英国的患者进行回顾性、非介入性病历回顾。共有70名医生（主要是血液学肿瘤学家[78.6%]）为196名符合条件的患者提供了数据。结果：患者主要为男性（62.8%），原发性骨髓纤维化（76.5%），平均年龄67.7岁开始FEDR。中位治疗持续时间为11.5个月（中位随访为13.8个月），近一半（49.5%）的患者在标签指示剂量为每日400mg时开始FEDR治疗。治疗6个月后，77.7%的患者出现症状缓解，66.8%的患者出现脾脏缓解。Kaplan-Meier估计中位无进展生存期和起始期总生存期分别为23.8个月（95% CI, 21.1-27.6）和29.8个月（95% CI, 23.9-NE）。结论：这些发现证明了FEDR在停用RUX的骨髓纤维化患者中的实际有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.